PUNEETCAPITAL

IFCI: Another turn around story.. Equity is Rs 630 crs whereas the NPA as per last Balance Sheet was Rs 3950 crs. Now what has changed in IFCI...... Equity remains at Rs.630 crs whereas during 06-07 IFCI had made major recoveries to the tune of Rs 2600 crs. leaving NPA at Rs 1366 crs. Now IFCI will turn in net positive before April 2007 . Now the reconciliation starts..... . NPA as of date ......... .... .............................................................. Rs 1366 crs Estimated recovery on account of Malvika Steel.......................... Rs 550 crs Sell of 7% stake of NSE ................................................................ Rs 780 crs Further value of NSE stake 5% will sell at 2000 though denied by mgmt Rs 800 crs Expected sell of land at Sultanpur 750 acrs .................................... Rs 800 crs IFCI has called for bids for its 750 acres land at Sultanpur. Th...

Stocks: Stunning winners of last 10 years...................... January 10, 2007 08:55 IST "We are never confused about why we exist. Although volume growth, earnings, returns and cash flow are critical priorities, our people understand those measurements are all simply the means to the long-term end of creating value for our share owners." -- the late Roberto Goizueta, ex-CEO, Coca-Cola. Goizueta would be turning in his grave if he took one look at our value creators of the past 10 years. When banks pay you 8% per annum, every few years a handful of stocks fetch anything between 100%-200% returns. They are the value creators Goizueta had in mind. These companies have patience, imagination, strategy and the stamina to deliver value for their shareholders. They give the real meaning to stock investing. Unfortunately, that is only part of the story. The nice part. While academics, analysts and consultants would have you believe that corporate governance, credibility, honesty ...

Mukesh Ambani-controlled Reliance Life Sciences is in for its first big ticket acquisition abroad. The Rs 1200 crore life sciences arm of the Rs 1 lakh crore Reliance Group would be paying up to £32.1 million (Rs 281 crore) to acquire a controlling stake in GeneMedix and its future ventures including the setting up of new companies. GeneMedix, the UK-based biotechnology company passed a resolution to this effect at a meeting of its shareholders. This was notified by a release on Thursday. GeneMedix is a biotechnology company focussing on core expertise of protein development scale-up and manufacture. It currently has a manufacturing unit in Ireland. However, when contacted Reliance official declined to comment. The acquisition could mean that Reliance is planning to expand its foothold in the UK and EU markets, said a source on condition of anonymity citing policy reasons. Reliance will buy 1.168 million (9.63 crore) shares with a value of about £14.6 million (Rs 127.9 crore), which...